摘要
孟鲁司特作为一种半胱氨酰白三烯受体拮抗剂，是支气管哮喘（简称哮喘）治疗的一线选择，尤其适用于阿司匹林过敏性哮喘和运动性哮喘的治疗，也可用于单一吸入糖皮质激素或联合长效β2受体激动剂与吸入糖皮质激素疗效不佳时的辅助治疗。最近，孟鲁司特已被报道具有不依赖其传统半胱氨酰白三烯受体拈抗作用的抗炎性，可作用于嗜酸粒细胞，单核细胞，尤其是对糖皮质激素不敏感的中性粒细胞。孟鲁司特可能具有更加广谱的抗炎性，对持续性哮喘，慢性阻塞性肺疾病，病毒性毛细支气管炎等疾病的治疗具有重要的临床应用价值。本文就孟鲁司特的半胱氨酰白三烯受体非依赖性抗炎作用机制及其临床研究进展综述如下。
Montelukast,as a cysteinyl leukotriene receptor antagonist,is one of the first line drugs of asthma treatment, is generally considered to have a niche application in the therapy of exercise and aspirin induced asthma. It is also used as an add-on therapy in patients whose asthma is not well controlled with inhaled corticosteroid as a monotherapy,or with the combination therapy of a long-acting ]32-agonist and inhaled corticosteroid. Recently, montelukast has been reported to possess anti inflammatory properties, apparently unrelated to conventional antagonism of cysteinyl leukotriene receptors, which enable montekulast to target eosinophils, monocytes, and especially the corticosteroid-insensitive neutrophils. Montekulast may have a broader spectrum of anti inflammatory activities, and have a significant clinical value in the chemotherapy of intermittent asthma, chronic obstructive pulmonary disease, viral bronehiolitis. This article discusses cysteinyl leukotriene independent anti-flammatory mechanisms of montelukast and reviews the research progress in recent years.
出处
《国际呼吸杂志》
2011年第19期1492-1495,共4页
International Journal of Respiration
